RT Journal Article
T1 Intravitreal Administration of Adalimumab-Loaded Poly(Lactic-co-Glycolic Acid) Nanoparticles: Effects on Biodistribution and Pharmacokinetics
A1 García Otero, Xurxo
A1 Varela Fernández, Rubén
A1 Cuartero Martínez, Andrea
A1 Gómez Lado, Noemí
A1 González Barcia, Miguel
A1 Mondelo García, Cristina
A1 Feitosa, Carolina
A1 Aguiar Fernández, Pablo
A1 Fernández Ferreiro, Anxo
A1 Otero Espinar, Francisco Javier
K1 Adalimumab
K1 Controlled releases
K1 In vivo distribution and pharmacokinetics
K1 Nanoparticles
K1 Poly(lactic-co-glycolic acid)
AB Adalimumab, a monoclonal antibody used for treating inflammatory diseases, including eye diseases, faces challenges in biodistribution and targeted delivery. Nanoparticle (NP)-based drug delivery systems have shown promise in enhancing the pharmacokinetic profiles of biologic drugs. This study aims to develop, and characterize intravitreal adalimumab-loaded poly(lactic-co-glycolic acid) (PLGA) NPs to improve antibody distribution and therapeutic efficacy. Characterization studies, morphological examination, and quantitative, stability, and physical properties are conducted. In vitro release kinetics are assessed using a dialysis membrane method. In vivo biodistribution is studied in rats after intravitreal administration by Positron Emission Tomography/Computed Tomography imaging. The optimized NPs were spherical (around 300 nm) with a surface charge of about −20 mV. Encapsulation efficiency and drug loading reach values close to 100%. Stability studies showed minimal changes in particle size and drug content. In vitro release showed a biphasic pattern with an initial burst release followed by sustained release. Safety studies indicated no significant cytotoxicity or adverse effects. The adalimumab-loaded PLGA NPs demonstrate favorable physicochemical characteristics, stability, and release profiles. In vivo distribution revealed a change in the antibody's distribution pattern after intravitreal administration via NPs encapsulation. These findings suggest the potential for enhanced therapeutic outcomes and warrant further investigation in disease-specific models to explore the clinical potential of this NP-based delivery system.
PB Wiley
YR 2025
FD 2025-01-27
LK https://hdl.handle.net/10347/42354
UL https://hdl.handle.net/10347/42354
LA eng
NO García-Otero, X., Varela-Fernández, R., Cuartero-Martínez, A., Gómez-Lado, N., González-Barcia, M., Mondelo-García, C., Feitosa, C., Aguiar, P., Fernández-Ferreiro, A. and Otero-Espinar, F.J. (2025), Intravitreal Administration of Adalimumab-Loaded Poly(Lactic-co-Glycolic Acid) Nanoparticles: Effects on Biodistribution and Pharmacokinetics. Small Sci., 5: 2400494. https://doi.org/10.1002/smsc.202400494
NO This work was partially supported by Ministry of Science and Innovation ofSpain (MICINN) [PID2022-142350OB-C21], Xunta de Galicia [Grupo deReferencia Competitiva, ED431C 2021/26 and IN607A 2023/004,IN607D-2021/01] and Instituto de Salud Carlos III (ISCIII, Spain) throughPI20/00719. X. G-O. acknowledge the support of Xunta de Galicia throughthe postdoctoral fellowship [ED481B-2023-063].
DS Minerva
RD 24 abr 2026